Solas BioVentures Research
Investment Thesis
Solas BioVentures is a life-sciences-focused venture capital firm based in Chattanooga, Tennessee, investing exclusively in biopharmaceuticals, medical devices, diagnostics, and digital health. The firm describes its approach as founder-centric, aiming to enable breakthrough medicine and meaningful technological innovation that transforms standard of care and patient outcomes. Solas backs "visionaries, contrarians, entrepreneurs, doctors, scientists" and combines medical, biotechnology, operations, and finance expertise with a proven medtech investment track record. Founded around 2014-2015, the firm has built a multi-decade reputation in the medical device and life sciences investing community, particularly around implantable devices, minimally invasive therapies, and women's/men's health technologies.
Stage Focus
Solas is primarily an early-stage investor, backing companies from seed through growth rounds. Portfolio evidence shows the firm entering at early financing rounds (e.g., Aegea Medical's $17M round) and following on into later rounds as companies mature, including co-leading Francis Medical's $80M Series C in January 2025. This suggests a stage range spanning Seed through Series C, with a clear bias toward the earliest institutional rounds in a company's life.
Check Size
Exact check size is not publicly disclosed. Observed deal sizes the firm has participated in range from a $17M early financing (Aegea Medical) up to an $80M Series C (Francis Medical, co-led with Arboretum Ventures), implying flexibility to write both small early checks and larger follow-on checks as portfolio companies scale.
Lead Tendency
Solas has a demonstrated pattern of leading or co-leading rounds. It led Aegea Medical's early financing and co-led Francis Medical's $80M Series C alongside Arboretum Ventures in January 2025, alongside new investors Orlando Health Ventures and existing investors Coloplast A/S and Tonkawa.
Recent Activity
- January 2025: Co-led Francis Medical's oversubscribed $80M Series C equity financing to advance the VAPOR 2 pivotal trial and U.S. commercialization of its Vanquish Water Vapor Ablation prostate cancer treatment.
- May 2025: Participated in a financing round for Areteia Therapeutics (asthma-focused drug discovery), per third-party deal databases.
- The firm manages roughly $165M in assets across at least two named funds (an "Emerging Healthcare Fund" and "Fund II"), plus earlier vintage "Fund I" investments and management-team SPVs ("Solas Sidecars").
Portfolio Highlights
Solas organizes its historical portfolio into several buckets: an active Emerging Healthcare Fund cohort (12 companies including ARC Therapeutics, Basking Biosciences, Vektor Medical, and Vesalio), a Fund II cohort, and a long list of Fund I and sidecar-vehicle investments. Notable exits include:
- NXThera, acquired by Boston Scientific for approximately $400M (2018) — a steam-based BPH ablation device.
- Aegea Medical, acquired by CooperSurgical/The Cooper Companies (Feb 2021) — its Mara Water Vapor Ablation System for heavy menstrual bleeding.
- Veran Medical, acquired by Olympus.
- Aerial BioPharma, acquired by Jazz Pharmaceuticals.
- NeuronEx, acquired by Acorda Therapeutics.
- Knopp Biosciences, whose ion-channel platform was acquired by Biohaven.
Team
Solas operates with a compact, multidisciplinary investment team combining clinical, legal, financial, and scientific backgrounds:
- David Adair, MD, MBA — Co-Founder & Managing Director
- Mark Hackett, JD — Co-Founder & Partner
- David Belitz — Partner
- Joshua Eckelberry, MBA — Partner
- Travis Manasco, MD — Partner
- Laurent Pacheco, MD, PhD, MBA — Team Member
- Julia Ray, BS — Controller
- Isaiah Reeves, PhD — Analyst
- Emma Heckenberg, PhD — Analyst
- Connielynn Hutchison — Office Manager
Advisory team members include Michael Ackermann, PhD; Lana Caron; and Michael Hoey, PhD, MBA (also a co-founder). The firm also engages Entrepreneurs in Residence, such as Mark Christopherson, a 30-year medical device veteran (Medtronic, Inspire Medical Systems, NxThera), who joined in December 2022 to support portfolio companies and serve as an ambassador to Minnesota's Medical Alley life-sciences ecosystem.
Decision Process
With multiple co-founders and partners, Solas appears to operate as a partnership-style decision process rather than a solo-GP model, consistent with the depth of its investment committee (two co-founders plus three additional partners).
Founder Preferences
Given its thesis language ("visionaries, contrarians, entrepreneurs, doctors, scientists") and its heavy concentration in physician-founded or clinically-driven medtech and biopharma companies, Solas appears to favor founding teams with deep clinical or scientific credibility — physicians, scientists, and technical operators building category-defining devices and therapeutics, often in partnership with experienced medtech operating executives it can supply through its network (e.g., EIR placements).
Geographic Focus
Headquartered in Chattanooga, Tennessee, with a satellite office in Research Triangle Park, North Carolina. The firm's activity — including EIR relationships tied to Minnesota's Medical Alley — suggests a national U.S. investment footprint rather than a strictly regional one, consistent with life-sciences hubs across the Southeast, Upper Midwest, and beyond.